Seeing Is Believing
Currently out of the existing stock ratings of Matt Miksic, 242 are a BUY (80.4%), 41 are a HOLD (13.62%), 18 are a SELL (5.98%).
Analyst Matt Miksic, currently employed at BARCLAYS, carries an average stock price target met ratio of 54.72% that have a potential upside of 18.58% achieved within 324 days.
Matt Miksic’s has documented 620 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LIVN, LivaNova PLC at 08-May-2025.
Analyst best performing recommendations are on ISRG (INTUITIVE SURGICAL).
The best stock recommendation documented was for ISRG (INTUITIVE SURGICAL) at 10/17/2022. The price target of $235 was fulfilled within 8 days with a profit of $44.88 (23.61%) receiving and performance score of 29.51.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$137
$3.42 (2.56%)
$125
1 months 16 days ago
(17-Apr-2025)
12/13 (92.31%)
$6.02 (4.60%)
390
Buy
$145
$11.42 (8.55%)
$133
1 months 16 days ago
(17-Apr-2025)
2/3 (66.67%)
$14.02 (10.70%)
133
Buy
$159
$25.42 (19.03%)
$158
1 months 16 days ago
(17-Apr-2025)
19/24 (79.17%)
$28.02 (21.39%)
465
Buy
$145
$11.42 (8.55%)
$135
1 months 16 days ago
(17-Apr-2025)
14/15 (93.33%)
$14.02 (10.70%)
298
Buy
$160
$26.42 (19.78%)
$127
2 months 29 days ago
(04-Mar-2025)
14/16 (87.5%)
$19.78 (14.11%)
487
Which stock is Matt Miksic is most bullish on?
Which stock is Matt Miksic is most reserved on?
What Year was the first public recommendation made by Matt Miksic?